RxDoctor Payments Data

David Burkart, MD

Vascular & Interventional Radiology · Kansas City, MONPI 1225078488

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Angiodynamics, Inc. at 26.2% of the total.

$56,398in general payments, 2019–2025

Across 888 payments — averaging $63.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$15K
  • Shockwave Medical, Inc$14K
  • Penumbra, Inc.$3K
  • Reflow Medical Inc$2K
  • Inari Medical, Inc.$2K
  • Medtronic$2K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$2,5354%
  • Speaking & faculty fees$12,05021%
  • Travel & lodging$12,10921%
  • Food & beverage$29,70453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.206$14,791
Shockwave Medical, Inc14$14,108
Penumbra, Inc.22$2,818
Reflow Medical Inc15$2,210
Inari Medical, Inc.16$1,999
Medtronic(2 entities)18$1,988
Cardinal Health 200 LLC42$1,834
Philips North America LLC7$1,799
Johnson & Johnson112$1,657
W. L. Gore & Associates, Inc.15$1,287
Terumo Medical Corporation10$1,187
Amgen62$1,182
Cordis US CORP.9$1,140
Nevro Corp.23$1,136
Silk Road Medical, Inc.7$872
Boston Scientific37$747
Boehringer Ingelheim33$627
Abbott10$549
Amarin Pharma, Inc.38$529
Pfizer18$408
AstraZeneca18$266
Kowa Pharmaceuticals America, Inc.21$253
Endologix LLC1$248
Surmodics, Inc.4$246
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)12$229
Daiichi Sankyo Inc.6$224
Sanofi-aventis U.S. LLC13$213
Novo Nordisk10$195
Bayer9$177
Actelion Pharmaceuticals US, Inc.12$137
United Therapeutics Corporation6$123
Alnylam Pharmaceuticals Inc.7$121
EKOS Corporation1$116
Sanofi5$97
Kiniksa Pharmaceuticals International, PLC6$93
CSL Behring5$84
Globus Medical3$72
Cleerly, Inc.1$67
Arbor Pharmaceuticals, Inc.4$52
Cardiva Medical, Inc.2$47
Esperion Therapeutics, Inc.3$44
Bardy Diagnostics, Inc.3$41
Kiniksa Pharmaceuticals, Ltd.2$39
Kestra Medical Technology Services, Inc.1$34
Atricure, Inc.1$33
Azurity Pharmaceuticals, Inc.2$32
Merck2$31
Regeneron Healthcare Solutions, Inc.2$30
Abiomed1$29
Astellas Pharma US Inc1$21
Cook Medical LLC1$19
Balt USA, LLC1$19
Biocompatibles, Inc.1$17
Medline Industries LP1$14
Vifor Pharma, Inc.1$13
Irhythm Technologies, Inc.1$12
Novartis1$12
Tactile Systems Technology Inc1$12
Cvrx, Inc.1$10
Merit Medical Systems Inc1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,398 in reported general payments places this provider in the 85th percentile of 81 vascular & interventional radiology providers in Missouri.

See all vascular & interventional radiology providers in Missouri

Medicare billing

Part B allowed, 2024
$257,902
Medicare patients
921
Services billed
2,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$13,197
ClopidogrelClopidogrel Bisulfate276$2,751
Rosuvastatin Calcium116$1,007
Gabapentin16$322
Atorvastatin Calcium35$264
Methylprednisolone11$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,657$13,19719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 vascular & interventional radiology providers in Missouri.

Other vascular & interventional radiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →